Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

baltaleucel-T

A preparation of autologous Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs), which have specific reactivity to the EBV antigens, latent membrane proteins (LMP) 1 (LMP1) and 2 (LMP2), EBV nuclear antigen (EBNA) and BamHI-A rightward frame-1 (BARF1), with potential immunomodulating and antineoplastic activities. Upon administration, baltaleucel-T targets and binds to EBV-expressing cancer cells specifically expressing the targeted antigens. This may kill LMP1/LMP2/EBNA/BARF1-expressing EBV-associated cancer cells. LMP1, LMP2, EBNA and BARF1 are tumor-associated antigens (TAAs) that are specifically associated with EBV infection, and play key roles in the proliferation of a variety of tumors.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:baltaleucel T
Epstein-Barr virus-specific LMP1/LMP2/EBNABARF1-targeting autologous cytotoxic T lymphocytes
Code name:CMD-003
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search